Guggenheim Reaffirms “Buy” Rating for Dermira (DERM)

Guggenheim reissued their buy rating on shares of Dermira (NASDAQ:DERM) in a research report report published on Tuesday, MarketBeat.com reports. They currently have a $20.00 price target on the biopharmaceutical company’s stock.

A number of other research firms have also recently issued reports on DERM. BidaskClub cut shares of Dermira from a buy rating to a hold rating in a research note on Friday, August 17th. Cantor Fitzgerald reiterated a buy rating and issued a $20.00 target price on shares of Dermira in a research note on Wednesday, September 5th. Zacks Investment Research cut shares of Dermira from a hold rating to a sell rating in a research note on Monday, August 13th. ValuEngine upgraded shares of Dermira from a strong sell rating to a sell rating in a research note on Tuesday, October 2nd. Finally, Mizuho reiterated a hold rating and issued a $10.00 target price on shares of Dermira in a research note on Tuesday, October 2nd. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $21.43.

NASDAQ:DERM opened at $11.12 on Tuesday. Dermira has a 1 year low of $6.98 and a 1 year high of $31.42. The company has a debt-to-equity ratio of 5.21, a current ratio of 5.29 and a quick ratio of 5.25. The company has a market capitalization of $458.70 million, a PE ratio of -2.53 and a beta of 0.96.

Dermira (NASDAQ:DERM) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.05. Dermira had a negative net margin of 496.49% and a negative return on equity of 184.43%. The company had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $0.80 million. As a group, sell-side analysts anticipate that Dermira will post -5.2 EPS for the current year.

In related news, Director Matthew K. Fust sold 4,000 shares of the business’s stock in a transaction that occurred on Friday, October 19th. The shares were sold at an average price of $13.75, for a total value of $55,000.00. Following the completion of the transaction, the director now owns 14,051 shares in the company, valued at approximately $193,201.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of DERM. Wells Fargo & Company MN raised its position in Dermira by 31.9% in the 1st quarter. Wells Fargo & Company MN now owns 32,772 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 7,924 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Dermira by 129.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 320,238 shares of the biopharmaceutical company’s stock worth $2,559,000 after purchasing an additional 180,947 shares during the last quarter. Xact Kapitalforvaltning AB bought a new position in Dermira in the 2nd quarter worth approximately $106,000. Aperio Group LLC raised its position in Dermira by 126.5% in the 2nd quarter. Aperio Group LLC now owns 24,828 shares of the biopharmaceutical company’s stock worth $228,000 after purchasing an additional 13,867 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. raised its position in Dermira by 919.0% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 161,307 shares of the biopharmaceutical company’s stock worth $1,484,000 after purchasing an additional 145,477 shares during the last quarter. Hedge funds and other institutional investors own 82.69% of the company’s stock.

About Dermira

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

Recommended Story: Beta

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply